Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
ATR-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "ATR-IN-1" in MCE Product Catalog:
Cat. No.: HY-12924
CAS No.: 1639974-69-8
ATR-IN-1 is a selective ATR inhibitor with an IC50 of 0.5 nM. ATR-IN-1 inhibits the growth of ATM-deficient melanoma. ATR-IN-1 shows no hERG inhibitory effect. ATR-IN-1 can be used for research on melanoma [1].
2
2 Cited Publications
Synonyms: M1774; ATR INhibitor 1
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ [1].
Cat. No.: HY-157764
CAS No.: 2925916-30-7
Target:
Research Areas:
PROTAC ATR degrader-1 is a ATR PROTAC degrader. PROTAC ATR degrader-1 promotes ubiquitination and degradation of ATR. PROTAC ATR degrader-1 facilitates the progression of cells through the G2/M phase, thereby impairing DNA repair and inducing Apoptosis. PROTAC ATR degrader-1 exerts anticancer effects against colorectal cancer either alone or in combination with Cisplatin (HY-17394). PROTAC ATR degrader-1 can be used in research related to colorectal cancer [1].
Cat. No.: HY-164496
CAS No.: 1161826-19-2
Target:
Research Areas:
KL-50 is an orally active N3-(2-fluoroethyl) imidazotetrazine DNA alkylating agent with selectivity for MGMT-deficient cells. KL-50 introduces a 2-fluoroethyl group at the O6 position of guanine, forming O6-(2-fluoroethyl) guanine (O6FEtG) lesions and further generating DNA interstrand crosslinks (ICLs). KL-50 induces DNA double-strand breaks, activates ATR-CHK1 and ATM-CHK2 DNA damage responses, and causes cell cycle arrest and micronucleus formation. KL-50 can be used for glioblastoma and DNA damage response research [1] .
Cat. No.: HY-174828
ATR/PARP1-IN-1 is a potent ATR and PARP1 dual inhibitor with IC50s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change [1].
Cat. No.: HY-147021
CAS No.: 1350456-66-4
Target:
Research Areas:
MC-Val-D-Cit-PAB-PNP is a peptide linker that can be used for the synthesis of Antibody-Drug Conjugates (ADCs). MC-Val-D-Cit-PAB-PNP can be used to construct antibody-drug conjugates loaded with ATR/CHK1 inhibitors [1].
Target:
Research Areas:
LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer [1] .
Cat. No.: HY-147021A
CAS No.: 1350456-64-2
Target:
Research Areas:
MC-D-Val-Cit-PAB-PNP is a peptide linker that can be used for the synthesis of Antibody-Drug Conjugates (ADCs). MC-D-Val-Cit-PAB-PNP can be used to construct antibody-drug conjugates loaded with ATR/CHK1 inhibitors [1].
Cat. No.: HY-144436
ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC50 value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .
Cat. No.: HY-173147
CDK2-IN-42 (Compound H63) is a CDK12 inhibitor with an IC50 value of 10 nM. CDK2-IN-42 has anti-ESCC (Esophageal Squamous Cell Carcinoma) cell activity. It can block transcriptional elongation, downregulate the core genes in the G1 phase to induce cell cycle arrest, and alter the CDK12-ATM/ATR-CHEK1/CHEK2 signaling axis, resulting in DNA damage. CDK2-IN-42 can effectively inhibit tumor growth in a xenograft mouse model of human ESCC KYSE150. CDK2-IN-42 holds great promise for research in the field of cancer [1].
Cat. No.: HY-111451S
Synonyms: M1774-d3; ATR INhibitor 1-d3
Cat. No.: HY-111451R
CAS No.: 1613200-51-3
Synonyms: M1774 (Standard); ATR INhibitor 1 (Standard)
Target:
Research Areas:
Tuvusertib (Standard) is the analytical standard of Tuvusertib (HY-111451). This product is intended for research and analytical applications. Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ [1].
Cat. No.: HY-181035
DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
